We previously reported that treatment with the cholinesterase inhibitor rivastigmine (3 mg, PO for 5 days) significantly attenuated "Desire for METH". Given that higher dosages of rivastigmine produce greater increases in synaptic ACh, we predicted that 6 mg should have more pronounced effects on craving and other subjective measures. In the current study, we sought to characterize the effects of short-term exposure to rivastigmine (0, 3 or 6 mg) on the subjective and reinforcing effects produced by administration of methamphetamine (METH) in non-treatment-seeking, METH-dependent volunteers. This was a double-blind, placebo-controlled, crossover study. Participants received METH on day 1, and were then randomized to placebo or rivastigmine on day 2 in the morning and treatment continued through day 8. METH dosing was repeated on day 6. The data indicate that METH (15 and 30 mg), but not saline, increased several positive subjective effects, including "Any Drug Effect", "High", "Stimulated", "Desire METH", and "Likely to Use METH" (all p's b 0.0001). In addition, during self-administration sessions, participants were significantly more likely to choose METH over saline (p b 0.0001). Evaluating outcomes as peak effects, there was a trend for rivastigmine to reduce "Desire METH" (p = 0.27), and rivastigmine significantly attenuated "Likely to Use METH" (p = 0.01). These effects were most prominent for rivastigmine 6 mg when participants were exposed to the low dose (15 mg, IV), but not high dose (30 mg, IV), of METH. The self-administration data reveal that rivastigmine did not alter total choices for METH (5 mg, IV/choice). Overall, the results indicate some efficacy for rivastigmine in attenuating key subjective effects produced by METH, though additional research using higher doses and longer treatment periods is likely needed. These data extend previous findings and indicate that cholinesterase inhibitors, and other drugs that target acetylcholine systems, warrant continued consideration as treatments for METH dependence.
Introduction
Methamphetamine (METH) is a highly addictive stimulant. According to the 2010 United States National Survey on Drug Use and Health (http://oas.samhsa.gov/nsduh.htm), the number of past month METH users was 353,000, and the number of recent new users of METH among persons aged 12 or older was 105,000. This latter value is disconcerting since it reflects~29 new users of METH each day! Our research group and others have completed several safety and preliminary efficacy trials of potential medications for treating METH dependence.
Despite these efforts, much work remains in identifying an effective pharmacotherapy. Recent review articles provide summaries of laboratory-based and outpatient trials conducted to date, and include lists of novel medications on the horizon (Elkashef et al., 2008; Haile et al., 2009; Kampman, 2008; Karila et al., 2010; Moeller et al., 2008; Rose and Grant, 2008; Vocci and Appel, 2007) , as well as more recent efforts to develop a vaccine for METH dependence (Shen et al., 2012) .
Although changes in the dopamine (DA) system have been most extensively studied, cholinergic transmission is also altered by drugs of abuse and both DA and acetylcholine (ACh) may contribute to psychostimulant reinforcement (Hurd et al., 1990; Mark et al., 1999a Mark et al., , 1999b . DA neurons express multiple types of muscarinic and nicotinic ACh receptors and an interplay of dopaminergic and cholinergic neurons in the nucleus accumbens allows coordinated functioning of these neurotransmitter systems. The role of nucleus accumbens cholinergic interneurons in the effects produced by cocaine was elucidated by recent optogenetic studies in rats (Witten et al., 2010) , and the importance of ACh systems in the effects produced by cocaine has been thoroughly summarized by Adinoff and colleagues (Adinoff et al., 2010; Williams and Adinoff, 2008 
